Vaulting a card at $0 and charging only when a clinician prescribes looks like a discount. It is a structural change to who carries the risk in telehealth.
By B.A. Utterback, Founder, PepScribe
ALT: Man managing a telehealth visit from his phone
The standard telehealth funnel starts with a consult fee. The patient pays $49 or $99 up front, a clinician reviews the case, and the answer might be no. The fee model is easy to defend on a spreadsheet: clinical review costs real money, and someone has to pay for it. But it prices the patient’s uncertainty at the exact moment their trust is lowest, and it quietly rewards platforms for maximizing paid visits rather than good prescribing decisions.
At PepScribe we run the opposite structure, and the mechanics are worth walking through because they generalize beyond our category.
The visit costs the patient nothing. At booking, the platform vaults a payment method with a $0 authorization, the same setup-intent primitive any subscription engineer knows. No charge exists yet. A licensed clinician then reviews the case and makes the prescribing decision. If the answer is no, the flow ends and no money ever moves. If the clinician prescribes, the saved card is charged for the treatment plan, and the patient saw the exact monthly price before their card was saved.
Three consequences fall out of that ordering.
First, the platform absorbs the cost of every declined visit. That sounds like a margin problem, and it is, until you notice what it buys: the company now has zero revenue attached to pushing a borderline patient through. The clinician’s no costs us money, and we planned for it. Decline rates get built into the unit economics the way payment-processor fees are, a few dollars spread across every approved plan. Incentive alignment is usually a slide-deck word. Here it is a line item.
Second, pricing has to be published, because charge-on-prescription only works if the patient already agreed to the number. Our monthly plans sit in a published band, $159 to $548 depending on therapy and dose, with medication, clinician oversight, and shipping in one figure. Transparent pricing is often framed as marketing. Structurally, it is a requirement of this billing model: you cannot charge a vaulted card on approval unless the amount was explicit up front.
Third, the model forces supply-chain discipline. When your revenue only exists after a clinician prescribes, the medication itself is the product you live or die on. Every dose we ship is compounded in the USA by licensed 503A pharmacies, the pharmacy class that prepares medication for an individual patient’s prescription, not 503B bulk production and not an international shipper. No hidden overseas supply chain. In a category where gray-market product is one search away, the sourcing standard is the moat.
There is an engineering bill for all of this. Charge-on-approval means billing has to subscribe to the clinical event stream: the charge fires when the prescribing decision lands, not when a form submits, so webhook reliability and idempotency stop being plumbing and become revenue correctness. Most checkout stacks assume money moves at the moment of intent. Moving it to the moment of clinical approval puts a state machine between the two, with a vaulted card on one side and a licensed clinician’s decision on the other, and that state machine is where this model is really built.
There is also a fraud-and-trust layer that tech readers will recognize. A $0 authorization filters out most drive-by abuse without charging anyone. LegitScript certification and BBB accreditation sit on top as third-party rails, the healthcare equivalent of SOC 2: slow to earn, easy to verify, and increasingly what ad platforms and answer engines check before they will surface you at all.
The obvious question is whether free visits attract unserious traffic. They do, some. The clinician review absorbs it, because that layer exists for clinical reasons and filters commercially as a side effect. The less obvious question is why the consult-fee model persists. My answer after running both spreadsheets: the fee model survives because it front-loads revenue, and front-loaded revenue flatters early-stage dashboards. Charge-on-prescription pays out later and only on real patients. It is the slower number, and the more honest one.
Telehealth is going to keep consolidating around whoever patients trust with a card before a diagnosis exists. The structural way to earn that is to make the card worthless until a licensed clinician says yes.
Compounded medications prepared by 503A pharmacies are prescribed for individual patients and are not FDA-approved drugs. Prescribing decisions at PepScribe are made by licensed clinicians.
AUTHOR BOX:
B.A. Utterback is the founder of PepScribe, a telehealth practice for peptide and hormone therapy. He is a former Emergency Medical Technician who went on to an executive career in technology, including creating medical mobile applications.
More at https://pepscribe.com/authors/b-a-utterback
